The excessive daytime sleepiness (EDS) Market will increase significantly from 2025 to 2035 as the increasing sleep disorders, lifestyle sleep disorders, and increased sleep health awareness drive the market growth. The excessive daytime sleepiness market is expected to be approximately USD 6,248 million in 2025 and is projected to be approximately USD 14,982 million by 2035 at a compound annual growth rate (CAGR) of 9.1% during the forecast period.
Among the most powerful drivers of market trends are diverse. They include the increasing diagnosis of sleep illnesses such as narcolepsy, sleep apnea, and restless leg syndrome that all manifest themselves as daytime fatigue. For instance, the increasing epidemic of obstructive sleep apnea in the elderly and obese has placed increasing pressure on the demand for high-quality forms of care.
Whereas, most critical market problem is underdiagnosis of sleep disorder which is resulting in delay of early treatment. It is impacting medical practitioners to invest in advertising activities and high-tech diagnostic units to improve early intervention and identification.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 6,248 million |
| Industry Value (2035F) | USD 14,982 million |
| CAGR (2025 to 2035) | 9.1% |
The market also divides between medical devices, drug treatments, and behaviour therapy. Pharmacological medications such as modafinil and solriamfetol are used most often for treatment of excessive daytime sleepiness due to narcolepsy and sleep apnea. Medical devices such as CPAP devices are the very root of treatment of sleep apnea and removal of excessive daytime sleepiness.
Cognitive behaviour therapy (CBT) is being developed as a new generation of non-pharmacologic treatment to improve sleep hygiene and remove daytime sleepiness. The strictest requirement for drug treatment is faced by patients with narcolepsy, while the gold standard to cure sleep apnea is the CPAP machine.
Explore FMI!
Book a free demo
Market dominance of EDS is managed by North America due to the fact that sleeping disorders exist in bulk there, medical facilities are strong, and susceptibility towards innovative treatment solutions is high. The USA leads in treatment and diagnosis availability with the number of sleep clinics offering up-to-date treatment increasing.
Further, growing awareness of campaigns by organizations such as the American Academy of Sleep Medicine (AASM) for treatment at an early stage also drive the growth of the market. Coverage of CPAP machines and prescription medication also remains a major driver in growing the availability of treatment.
Telemedicine is being developed in sleep disorder treatment by North American firms with digital health solution. AI diagnostic equipment and sleep pattern trackers, wearables, are gaining popularity too. The patients can track their sleeping pattern and get appropriate medical intervention at the right time.
Europe has a large EDS market for treatment, and preference markets are French, German, and United Kingdom. There is need in Germany for sleep apnea treatment and specifically CPAP therapy and life change. In France, there has been investment in public health policy to enable promotion of sleep hygiene, and therefore diagnosis is begun and application of the treatment.
United Kingdom's National Health Service (NHS) has invested a lot in sleep disorder research with immense interest, and drug development has followed suit.
Stringent regulation policies by the European Medicines Agency (EMA) ensure effectiveness and safety in drug therapy, and innovative reimbursement schemes promote access to medical devices for the treatment of sleep disorders. The continent is also shifting towards behavioural therapy alternatives, as awareness of mental illness grows.
The Asia-Pacific market will be the most likely to see the most growth in the market of EDS because of growing rates of undiagnosed sleep disorders, lifestyle, and urbanization. Some of the key markets of the region are Japan, India, China, and South Korea with growing investment in the healthcare sector as well as greater awareness towards sleep health.
China experienced colossus growth in sleep apnea diagnosis and therefore for CPAP machines and drugs. India's growing middle class is increasingly spending money on private healthcare services, including the treatment of sleep disorders, which are growing more fashionable.
Japan's ageing population is dominating the market because old people are more prone to sleep disorders. South Korea has been a hotbed of innovation in sleep technology, where local firms develop intelligent sleep monitors and AI-based solutions.
While the market is enlarged multifold, the Asia-Pacific region falls behind in affordability and accessibility of sleep disorder care. Governments and private firms are now accelerating diagnostic center numbers and adding sleep health to high-priced public health programs.
Challenge
Underdiagnosis and Lack of Awareness
We observe that most of the patients suffering from daytime sleepiness go undiagnosed because they are lacking both access and information to procure consulting sleep physicians. Sleep disorders are therefore related to overall notions of stress or fatigue, and proper consultation of medicine is thereby delayed. This underdiagnosis leads to such treatment with a huge gap, particularly in the third world where the health care system itself is in its infancy.
Physicians and patient groups are re-fighting with education campaigns and wider screening for sleep disorders. Further technological innovation in home uses of sleep monitoring is within reach to allow more patient-led diagnosis, motivating them to attend the physician sooner.
Opportunity
Growth in Digital Health Solutions
Greater use of digital health solutions is the biggest opportunity for the EDS market. Artificial intelligence-powered diagnosis software, body-worn sleep-tracking monitors, and telemedicine consultations are revolutionizing treatment of sleep disorders with greater accessibility and ease of treatment. Financed smart CPAP machines are monitoring quality of sleep and adjusting pressure levels automatically for greater long-term effectiveness of treatment.
Apart from this, new wake-promoting agents that are less toxic are also being launched by pharmaceutical companies for more widespread patient groups. Sleep disorder-dedicated medications are also being investigated intensively, allowing for individualized medicine to a particular sleep pattern and gene expression profile.
The CPAP machine business for EDS grew significantly between 2020 and 2024 with increasing diagnoses of narcolepsy and sleep apnea, increased innovation in drug therapy, and adoption of technology in the war against sleep health. Demand for CPAP machines grew in the target market due to increased awareness levels as well as insurance cover availability.
Forward to 2025 to 2035, the market will shift towards more and more personalized, technology-enabled solutions. Sleep diagnosis using AI, wearables, and digital therapeutics will be the norm. The pharma industry will see innovation for lower side effects and improved outcomes. As healthcare systems globally adopt the need for sleep health, early detection and wider availability of treatment will be policies that will frame the future of the EDS market.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Regulatory bodies impose tougher controls on managing sleep disorders, and this placed tougher approval schemes on new medication. For instance, the USA FDA imposed tougher controls on narcolepsy medication, and this placed tougher accessibility for some of the treatments in the market. |
| Technological Advancements | Between 2020 and 2024, wearables developed in a manner that sleeping habits were constantly tracked to support early diagnosis of EDS. Wearable technologies such as Fitbit and Apple Watch had sleep tracking features that were mainstream within the consumer market. |
| Treatment Modalities | Pharmacological treatment through administration of wakefulness-promoting and stimulant agents was the most common method used to treat EDS. Drugs such as modafinil and armodafinil were commonly prescribed during this time. |
| Patient Awareness and Education | Public education campaigns regarding sleep disorders have been more in the limelight, thereby increasing moderate numbers of patients reporting to physicians with EDS symptoms. The National Sleep Foundation conducted workshops to create public awareness of the need for sleep health. |
| Diagnostic Procedures | Polysomnography (sleep studies) in specialty clinics have been the standard for diagnosis of EDS-associated conditions, including obstructive sleep apnea (OSA). The studies were not easily accessible because they were expensive and only available in specialty clinics. |
| Market Growth Drivers | Growing prevalence of sleep disorders, including OSA and narcolepsy, and the growing geriatric population have fueled the demand for EDS treatments. The market grew slowly because of such conditions. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Governments around the world are to implement end-to-end policies in addressing sleep health, like the early identification and treatment of the needs for excessive daytime sleepiness (EDS). The European Union, for instance, is to enact a law promoting the use of certified medical devices in treating sleep apnea with increased safety and effectiveness levels. |
| Technological Advancements | The use of artificial intelligence (AI) in the diagnosis of sleep can transform the management of EDS. AI platforms will probably analyze entire sleep databases to provide customized treatment advice. For example, companies like ResMed are working on AI algorithms that will enhance the accuracy of sleep apnea diagnosis. |
| Treatment Modalities | Shifting to non-pharmacological intervention is also on the cards, with cognitive-behavioural treatment for insomnia (CBT-I) taking center stage increasingly as a first-line intervention. Therapeutic mobile platforms, like those being developed by Pear Therapeutics, will be able to offer CBT-I programs at low cost to patients globally. |
| Patient Awareness and Education | There will be more educational programs that will result in a greater percentage of reported cases of EDS. Businesses and organizations will be selecting sleep health programs since sleep will enable them to work smarter and think sharper. Corporate wellness programs, for instance, would consist of sleep-educational modules on improved sleep habits of employees. |
| Diagnostic Procedures | Home sleep testing devices will be commonplace, providing affordable, user-friendly diagnostic technology. Philips and others are creating home sleep test kits so patients can perform sleep studies at home, which improves diagnosis and early intervention. |
| Market Growth Drivers | The market will also increase at a rapid rate, led by the growth in technology, healthcare expenditure, and growing awareness of the importance of mental well-being. Telemedicine use for sleep consultation and the development of new therapeutics intended for the detection of etiology of EDS are likely to propel market growth. |
United States has witnessed rapid growth of the EDS market owing to high incidence of sleep disorders and increased awareness about sleep wellness. The market growth has been facilitated through the use of highly advanced diagnostic equipment and availability of plenty of treatment options. For instance, the use of CPAP equipment in OSA patients is now routine.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 9.1% |
In the United Kingdom, the EDS market has been consistently expanding with the help of the efforts of the National Health Service (NHS) to enhance the treatment of sleep disorders. The inclusion of sleep clinics in the NHS system has made it easy for people to access diagnosis and treatment. The "Sleepio" program by the NHS, for example, provides digital CBT-I to patients with insomnia.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 9.2% |
The European Union has seen varied growth patterns in the EDS market due to the varying healthcare infrastructures of member states. Germany and France have invested significant amounts in sleep research and public campaigns, which have been repaid in terms of greater diagnosis and treatment rates. Germany, for instance, has a "Somnio" program for early detection of sleep disorders among shift workers.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 9.0% |
Japan's EDS market grew with culture-fact-based presumptions regarding productivity and understanding effects of sleep disorders on work. Efforts to prevent "karoshi" (death from overwork) have been made by the government in the form of promoting improved sleep health. Organizations have begun providing nap rooms and flexible work schedules to help fight EDS among employees.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 9.2% |
South Korea experienced more growth in the EDS market since it is high-tech-aware and buys wearable devices to monitor sleep. The government has created more programs to raise awareness of the need for sleep, so diagnosis and treatment of sleep disorders have increased. For instance, the Korean Society of Sleep Medicine has initiated programs to increase awareness of sleep hygiene in the population.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 9.1% |
Obstructive Sleep Apnea (OSA) dominates the market for excessive daytime sleepiness because OSA is one of the most common sleep disorders that make an extraordinary contribution to one's daily functioning. Awareness about OSA diagnosis and its association with cardiovascular diseases, diabetes, and cognitive function has been propelling its market.
Continuous positive airway pressure (CPAP) treatment remains the most frequent treatment, and CPAP devices are becoming more popular with auto-adjusting pressure and in-line humidification.
In addition to that, the improved availability of home sleep apnea testing (HSAT) machines has provided an easy opportunity for individuals to get diagnosed from home. Also, the better availability of sleep laboratories and specialized centers across North America and Europe is contributing towards rising demand for OSA treatment. Further, the expanding public and private health insurance coverage for sleep apnea treatment is significantly contributing to market growth.
Narcolepsy, a comparatively rare disorder, is seeing strong market growth with expanding research activity toward newer treatment methodologies. The efficacy of sodium oxybate as an initial-line drug therapy of excessive daytime sleepiness in narcolepsy continues with benefits in enhancing nocturnal sleep quality and curtailing daytime sleepiness. The desire of pharma companies to launch low-sodium products for treating sodium consumption issues is therefore driving further pharma development.
Alongside this, therapy-dependent medications like modafinil and amphetamine salts also remain under heavy prescription on an upgraded level, particularly in the USA Favorable approval by regulatory agencies to newer extended-release versions is growing the market for narcolepsy therapeutics. Increased visibility of patient assistance programs by pharma organizations is also playing effectively towards segment growth.
Therapeutic agents like stimulants, antidepressants, and sodium oxybate are the leaders in the market for excessive daytime sleepiness due to their enormous prescription and ease of dosing. Stimulants like modafinil and armodafinil are still the first-line agents due to their wake-promoting activity with minimal risk of dependence. Increasing physician and patient acceptance of non-amphetamine stimulants is driving growth in this segment.
Although products like CPAP machines and oral appliances are instrumental in controlling sleep apnea-induced daytime sleepiness, their penetration remains low owing to patient cooperation and higher upfront costs. Technological developments in battery-operated and friendly-user CPAP products and AI-based diagnostic equipment are, however, promoting the uptake of sleep therapy devices.
Sleep specialty centers and laboratories are still ruling the value chain for treating excessive daytime sleepiness because both of these offer end-to-end therapeutic as well as diagnostic services. Sleep studies conducted here ensure precise examination, leading to effective treatment schemes. An increase in the opening of sleep centers in advanced economies such as the United States, Germany, and Japan is also fueling the segment.
Conversely, home care settings are gradually gaining traction with the growing utilization of remote monitoring devices and home sleep testing kits. Home treatment is most common in the CPAP segment, where portable and travel-friendly devices are simplifying the lives of patients. With telemedicine becoming part of sleep disorder treatment increasingly, home care settings are poised to witness steady growth over the next few years.
Excessive Daytime Sleepiness (EDS) is a very dynamic competitive market with dominance by big multinational companies and with a mix of regional manufacturers driving industry expansion. There are no dominant players with wide market shares, and firms are competing in innovative therapeutic products and expanding indications for the treatment of EDS secondary to narcolepsy, sleep apnea, and idiopathic hypersomnia.
The companies specialize in novel mechanisms of action, patient compliance, and complete takeover of the sleep disease. The rivals are incumbent pharma players and new entrants, all in a race to the edge of the paradigm break in EDS treatment.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Jazz Pharmaceuticals | 25-30% |
| Teva Pharmaceutical | 15-20% |
| Avadel Pharmaceuticals | 10-15% |
| Axsome Therapeutics | 5-10% |
| Bioprojet Pharma | 3-7% |
| Other Companies (combined) | 25-35% |
| Company Name | Key Offerings/Activities |
|---|---|
| Jazz Pharmaceuticals | Provides Xyrem and Xywav, sodium oxybate products approved for narcolepsy-associated EDS and cataplexy; Xywav also approved for idiopathic hypersomnia. Emphasizes sodium content reduction and broadening therapeutic uses. |
| Teva Pharmaceutical | Produces Provigil (modafinil), a wakefulness-promoting drug used for EDS with narcolepsy, obstructive sleep apnea, and shift work disorder. Focuses on generic versions to make it more accessible. |
| Avadel Pharmaceuticals | Formulated Lumryz, a nightly sodium oxybate product approved to treat cataplexy or EDS in patients with narcolepsy who are 7 years and older. Emphasizes patient convenience with its once-nightly dosing regimen. |
| Axsome Therapeutics | Markets Sunosi (solriamfetol), a norepinephrine and dopamine reuptake inhibitor indicated to enhance wakefulness in adults with EDS caused by sleep apnea or narcolepsy. Dual-acting mechanisms for symptom relief. |
| Bioprojet Pharma | Offers Wakix (pitolisant), a histamine-3 receptor antagonist/inverse agonist for EDS in patients with narcolepsy. Invests in wake-promoting therapies through histaminergic pathways. |
Key Company Insights
Jazz Pharmaceuticals (25-30%)
The current leader among the EDS players is Jazz Pharmaceuticals with its sodium oxybate drugs, Xyrem and Xywav, that treat narcolepsy with EDS and cataplexy. FDA approval of Xywav in idiopathic hypersomnia places Jazz at the vanguard of broadening the therapeutic window for heterogeneous sleep disorders.
Sodium reduction in Xywav by Jazz avoids cardiovascular effects of sodium oxybate long-term therapy. The firm's interest in broadening therapeutic application and strengthening patient protection is proof of its market leadership in the EDS category.
Teva Pharmaceutical (15-20%)
Teva Pharmaceutical markets Provigil (modafinil), a wake-promoting drug of routine prescription for EDS with connections to narcolepsy, obstructive sleep apnea, and shift work disorder. With generic release, Teva enhances availability and affordability for patients in need of treatment for EDS. The company's efforts towards the development of cost-cutting medicines enhance global healthcare objectives of enhancing patient access to required medicine.
Avadel Pharmaceuticals (10-15%)
Avadel Pharmaceuticals introduced Lumryz, once-daily intranasal single-dose sodium oxybate, for the treatment of EDS or cataplexy in adult and pediatric and adolescent narcolepsy 7 and above. Dosage regimen of Lumryz is another positive aspect over middle-of-the-night dosage regimen with better patients' compliance towards quality of life. The success shows Avadel's move towards patient-focused treatment of sleep disease.
Axsome Therapeutics (5-10%)
Axsome Therapeutics markets Sunosi (solriamfetol), a dual mechanism reuptake blocker of dopamine and norepinephrine, for use in the promotion of wakefulness in adult patients with EDS with either obstructive sleep apnea or narcolepsy.
The unique mechanism of action of Sunosi impacts multiple systems regulating wakefulness, presenting a solution to EDS patients who may be refractory to standard stimulants. Axsome's commitment to the creation of new therapeutic opportunities is in line with its goal of furthering the treatment of EDS.
Bioprojet Pharma (3-7%)
Bioprojet Pharma is also selling Wakix (pitolisant), a histamine-3 receptor antagonist/inverse agonist used to treat EDS in patients with narcolepsy. Through the modulation of action along the histaminergic pathway, Wakix provides a non-stimulant treatment for EDS that is attractive to those patients who wish to avoid the older, more traditionally employed stimulant medications.
Bioprojet's focus on modulation therapies along the histaminergic pathway is a reflection of its forward-thinking approach to the EDS market.
Other Key Players (25-35% Combined)
Beyond these leading companies, several other firms contribute significantly to the EDS market, fostering innovation and addressing unmet medical needs. These include:
The overall market size for excessive daytime sleepiness market was USD 6,248 million in 2025.
The excessive daytime sleepiness market is expected to reach USD 14,982 million in 2035.
The rising prevalence of sleep disorders, increasing awareness about excessive daytime sleepiness, and advancements in treatment options drive the demand for the Excessive Daytime Sleepiness Market during the forecast period.
The top 5 countries which drive the development of the excessive daytime sleepiness market are the USA, UK, Germany, China, and Japan.
On the basis of treatment, pharmaceutical drugs, particularly stimulants and wake-promoting agents, are expected to command a significant share over the forecast period.
Healthcare Biometrics Market Trends - Growth, Demand & Forecast 2025 to 2035
Healthcare API Market Growth – Trends & Forecast 2025 to 2035
Gastrointestinal Stent Market Growth – Trends & Forecast 2025 to 2035
Gel Implants Market Analysis - Trends, Share & Forecast 2025 to 2035
3D Printing Dental Devices Market Growth - Trends & Forecast 2025 to 2035
3D Printed Hip and Knee Implants Market Growth - Trends & Forecast 2025 to 2035
Excessive Daytime Sleepiness Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
